Download presentation
Presentation is loading. Please wait.
Published byReginald Barton Modified over 8 years ago
2
PATIENT CASE Module 4 Date of preparation: June 2015 HQ/EFF/15/0024h
3
A case of breakthrough cancer pain in a patient with prostate cancer Dr Andrew Davies Consultant in Palliative Medicine St. Luke’s Cancer Centre, Guildford (UK) Oncology referral
4
Patient history Male 65 years old Retired quantity surveyor No significant past medical history Diagnosed locally advanced prostate cancer 2012 – treated with anti-androgen therapy, radiotherapy Diagnosed metastatic prostate cancer 2014 – treated with further anti-androgen therapy, chemotherapy Current treatment dexamethasone
5
Current pain/illnesses Pain pelvis for 3/12 – pain present all the time (“mild” in intensity), but worse on walking (“severe” in intensity) Pain prevents him walking his dog (or walking > 10 m for any reason); no pain at night (sleeps well) Current medication – modified release morphine sulfate 30 mg twice a day, immediate release morphine sulfate 10 mg as required Clinical oncologist gave a course palliative radiotherapy to pelvis (no effect)
6
Current pain/illnesses
7
Clinical examination and pain assessment Patient looks well ECOG performance status 4 (limited by pain) No bone tenderness No neurological signs [BAT – Breakthrough Pain Assessment Tool completed]
8
Clinical judgment Breakthrough pain – volitional, incident sub-type
9
Therapeutic approach Modified release morphine sulfate titrated to 40 mg twice a day Oral transmucosal (sublingual) fentanyl citrate prescribed / titrated to 400 mcg as required – to be taken when quick pain relief required, and prior to walking (short episodes); dose titrated to optimal dose (i.e. effect vs side effects) Oral immediate release morphine titrated to 7.5 mg as required – to be taken prior to walking (longer episodes); dose titrated to optimal dose (i.e. effect vs. side effects)
10
Follow-up Patient reviewed on weekly basis (shared care between palliative care team and general practitioner) Exercise tolerance increased to 100 m (no adverse effects from increased dose of morphine) Oral transmucosal fentanyl citrate effective treatment for BTcP (quicker onset of action, better effect, shorter duration of effect - as compared to oral morphine) Oncology review regarding role of bisphosphonate / alternative anti-cancer treatment – referred by palliative care team
11
Conclusions BTcP improved with a combination of strategies (i.e. increase in background medication, use of transmucosal fentanyl citrate formulation) Multidisciplinary team engagement is essential for optimal management of BTcP
12
Thank you
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.